For the third time Chimera Biotec supports the scientific community with a contest on ultra-sensitive immunoassays: the third Immunolympics are open
The contest seeks to find potential solutions to today's scientific challenges using ultra-sensitive immunoassays.
Think about possible applications and win an Imperacer feasibility study to push forward your research project.
It's the third time that Germany-based Chimera Biotec inspires the scientific community with a contest on ultra-sensitive immunoassays.
The contest seeks to find solutions to today's scientific challenges using ultra-sensitive immunoassays.
Ultra-sensitive Biomarker quantification based on immunoassays has become an essential tool in drug development, as well as in various research areas (CNS, cancer, inflammation, vaccines, etc.).
It has been estimated that 80-90% of all the proteome cannot be quantified using conventional Elisa technologies.
The Immunolympics aims to inspire the scientific community on their hunt for relevant biomarkers, proteins and peptides deep down in the proteome.
Imperacer is an assay format for the quantification of low abundant biomarkers.
Scientists are invited to Brainstorm with Chimera Biotec about relevant targets and biomarkers and throw some challenging new biomarkers into the arena.
Rohan de Silva was the winner of the contest for his study on neurological disorders.
In a feasibility study, Chimera Biotec supported de Silva's research on Alzheimer's disease.
Win an Imperacer feasibility study to push forward your research project.
Interested scientists are invited to participate online, via the Chimera website (linked here).
